Characteristics of Prior Authorization Policies for New Drugs in Medicare Part D.

Naci, Huseyin; Forrest, Robin; Zhai, Mike; Stofesky, Amanda R; Kesselheim, Aaron S

Naci, Huseyin; Forrest, Robin; Zhai, Mike; Stofesky, Amanda R; Kesselheim, Aaron S.

Afiliación

Naci H; Department of Health Policy, London School of Economics and Political Science, London, United Kingdom.
Forrest R; Department of Health Policy, London School of Economics and Political Science, London, United Kingdom.
Zhai M; Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Stofesky AR; Dartmouth Institute for Health Policy and Clinical Practice, Dartmouth College, Lebanon, New Hampshire.
Kesselheim AS; Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

JAMA Health Forum ; 4(2): e225610, 2023 02 03.

Article en En | MEDLINE | ID: mdl-36826829

This cross-sectional study examines the characteristics of prior authorization policies for new drugs in Medicare Part D to understand whether they are consistent with US Food and Drug Administration indications.

Asunto(s)

Medicare Part D; Estados Unidos; Autorización Previa; Cobertura del Seguro; Políticas

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Medicare Part D Tipo de estudio: Observational_studies / Prognostic_studies País/Región como asunto: America do norte Idioma: En Revista: JAMA Health Forum Año: 2023 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google